Compositions and methods for treating chronic myelomonocytic leukemia
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorEric Padron
Life of this patent
Estimating the term…
Abstract
As disclosed herein, the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is overexpressed and prognostic in Chronic Myelomonocytic Leukemia (CMML). MALAT1 depletion is disclosed herein as therapeutic strategy for treating CMML and other MALAT1 overexpressing leukemias. Also disclosed herein is a method of treating a subject with a leukemia that involves co-administering to the subject a MALAT1 silencing agent and a therapeutically effective amount of a differentiation agent, such as all-trans retinoic acid (ATRA).
Claims7
A method for treating chronic myelomonocytic leukemia (CMML) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a MALAT1 antisense oligonucleotide or siRNA and a therapeutically effective amount of retinoic acid, wherein the MALAT1 antisense oligonucleotide or siRNA comprises a nucleic acid sequence that is complementary to a contiguous portion of human MALAT1 RNA 14 to 100 base pairs in length.
A composition, comprising a therapeutically effective amount of a MALAT1 antisense oligonucleotide or siRNA and a therapeutically effective amount of retinoic acid, wherein the MALAT1 antisense oligonucleotide or siRNA is complementary to a contiguous portion of human MALAT1 RNA 14 to 100 base pairs in length.
Dependencies are inferred from the claim text.